Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Key Points

• Sarasin & Partners LLP decreased its holdings in Pfizer Inc. by 1.2%, owning 1,454,498 shares after selling 18,354 shares in the second quarter.
• Pfizer recently reported earnings of $0.78 per share, surpassing analysts' expectations of $0.58, with a revenue of $14.65 billion during the last quarter.
• The biopharmaceutical company announced a quarterly dividend of $0.43 per share, yielding 7.2% with a payout ratio of 91.49%.

Sarasin & Partners LLP decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,454,498 shares of the biopharmaceutical company's stock after selling 18,354 shares during the quarter. Sarasin & Partners LLP's holdings in Pfizer were worth $35,257,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of PFE. Trust Co of the South increased its position in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after acquiring an additional 441 shares in the last quarter. William B. Walkup & Associates Inc. increased its position in shares of Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after acquiring an additional 454 shares in the last quarter. Members Trust Co grew its position in Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares in the last quarter. Sutton Place Investors LLC grew its position in Pfizer by 5.6% during the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares in the last quarter. Finally, Fragasso Financial Advisors Inc grew its position in Pfizer by 2.2% during the 2nd quarter. Fragasso Financial Advisors Inc now owns 22,460 shares of the biopharmaceutical company's stock worth $544,000 after purchasing an additional 480 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE PFE opened at $23.88 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $24.73 and a 200 day simple moving average of $24.25. The company has a market cap of $135.77 billion, a P/E ratio of 12.70, a P/E/G ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio is presently 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.